Renascience

Renascience OCF/Debt

The Operating Cash Flow to Debt Ratio of Renascience (4889.T) as of Nov 2, 2026 is -64.73 %. In the previous year, Operating Cash Flow to Debt Ratio was -91.94 % — a change of -29.59% (higher).

OCF/Debt

-64.73 %

YoY

-29.59%

Last updated:

Operating Cash Flow to Debt Ratio of Renascience is 2024 -64.73 % . Operating Cash Flow to Debt Ratio of Renascience was 2023 -91.94 % . It decreases by -29.59% higher compared to the previous year.

The Renascience OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2020
-46.92 JPY
Jan 1, 2021
-18.76 JPY
Jan 1, 2022
-115.69 JPY
Jan 1, 2023
-91.94 JPY
Jan 1, 2024
-64.73 JPY
The Renascience OCF/Debt history
YEAROCF/DebtYoY
-64.73 %-29.59%
-91.94 %-20.53%
-115.69 %+516.54%
-18.76 %-60.01%
-46.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Operating Cash Flow to Debt Ratio of Renascience is -64.73 % in 2024.

Operating Cash Flow to Debt Ratio of Renascience changed from -91.94 % to -64.73 %, representing a -29.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Renascience since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Renascience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Renascience

All Key Metrics — Renascience